New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of coronavirus ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

No signs of a recurrence from the cancer that once threatened Bailey’s life. Nothing to see here. “I keep telling her: don’t ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.